For locally advanced (stage II–III) lung cancer, Chinese oncology teams helped define the modern sequence: 2–4 cycles of PD-1 immunotherapy (with or without chemotherapy) to shrink the tumour first, then a minimally invasive resection on a down-staged, easier-to-operate field. China's domestic PD-1 agents made this protocol affordable as well as effective.
| Option | Best suited for | What it means in practice |
|---|---|---|
| Neoadjuvant immunotherapy + chemotherapy, then VATS resection | The flagship pathway | Chinese-led trials helped define it; domestic agents make it affordable. |
| Neoadjuvant immunotherapy alone, then surgery | Selected PD-L1-high tumours | Lighter toxicity; used in specific trial protocols. |
| Upfront surgery, then adjuvant immunotherapy | Small stage II tumours | Chosen when delay is riskier than downstaging benefit. |
| Typical China cost (reference only) | US$12,000–28,000 for the complete journey (neoadjuvant cycles + surgery), depending on agent choice and cycle count |
|---|---|
| Typical in-hospital stay | Neoadjuvant phase: outpatient; surgical admission 4–6 days |
| Return-to-travel timeline | Treatment window 3–5 months end-to-end; patients usually stay in China 6–10 weeks across the whole pathway |
Costs are indicative ranges for international self-pay patients at major Chinese hospitals; final quotes depend on the hospital, implant/medication choice and case complexity. WellVoyage locks a written all-in quote before you commit.
A tumour too large for immediate surgery. Two cycles of neoadjuvant chemo-immunotherapy in Shanghai shrank it by 60%; VATS lobectomy followed, and pathology found almost no viable tumour left.
His Dutch team planned chemoradiation alone. He sought a second opinion and a Chinese multidisciplinary board offered the conversion-to-surgery pathway — neoadjuvant immunotherapy, then a minimally invasive resection.
One centimetre of growth made the difference between resectable and not. Neoadjuvant therapy pulled her firmly into the resectable column; the operation happened fourteen weeks after her first email.
Shoulder pain misdiagnosed as arthritis for six months. Neoadjuvant chemo-immunotherapy downstaged the tumour away from the chest wall, and a minimally invasive resection completed the treatment.
Mediastinal nodes made her case complex. A Chinese tumour board sequenced immunotherapy, then surgery, then adjuvant therapy — a plan her Casablanca oncologist now co-manages by email.
Sleeve resection after neoadjuvant response preserved his lobe. Pathology staged him down from IIIA to ypT2N1 — a result his family had been told to abandon hope of.
Imaging suggested the tumour had melted; surgery found microscopic residue. That residual is why she chose a team that operates even after beautiful scans — the microscope sees what PET cannot.
Your Chinese oncologist selects from both imported and domestic agents based on PD-L1 expression and your budget; domestic agents are why this pathway is affordable — WellVoyage presents the options with written prices before anything is administered.
Not necessarily. A common pattern is 2 cycles in China, surgery, then continuing adjuvant dosing at home under your local oncologist using the Chinese records — WellVoyage prepares the translated handover pack.
WellVoyage translates your records, obtains independent specialist opinions, and locks a transparent written quote — before you book a flight.
Start with a Free Case Review →